News from Puracap:
Humanwell Healthcare Group and PuraCap Pharmaceutical LLC to Acquire Epic Pharma, LLC
Purchase Will Expand Humanwell's and PuraCap's US Generics platform SOUTH PLAINFIELD, N.J., March 31, 2016 /PRNewswire/ — Humanwell Healthcare Group and PuraCap Pharmaceutical LLC announced today that the companies have entered into a definitive agreement to acquire 100% of the membership interests of Epic Pharma, LLC of Laurelton, NY for $550 million. The acquisition will further […]
PuraCap Pharmaceutical LLC Announces Acquisition of Blu Pharmaceuticals LLC and Blu Caribe
Purchase expands PuraCap's presence in both US and Global Markets SOUTH PLAINFIELD, N.J., March 24, 2016 /PRNewswire/ — PuraCap Pharmaceutical LLC announced yesterday the acquisition of Blu Pharmaceutical LLC and Blu Caribe Inc creating PuraCap International LLC, a joint venture between PuraCap and Dangdai International Group Co., Ltd. This acquisition will expand PuraCap's world-class manufacturing expertise […]
HumanWell PuraCap Pharmaceutical LLC Announces Successful FDA Inspection
SOUTH PLAINFIELD, N.J., Nov. 12, 2015 /PRNewswire/ — PuraCap Pharmaceutical LLC is pleased to announce that the US Food and Drug Administration (FDA) has completed a successful inspection of its affiliated soft gelatin capsule manufacturing facility, Humanwell PuraCap Pharmaceutical (Wuhan) Co, Ltd, located in Wuhan, Hubei Province China. The inspection confirmed that the site is compliant […]
PuraCap® Pharmaceutical LLC Introduces New EpiCeram-L™ Lip Care
SOUTH PLAINFIELD, N.J., Nov. 4, 2015 /PRNewswire/ — PuraCap Pharmaceutical LLC announced today the introduction of a new product, EpiCeram-L™ Lip Care, a unique lip care formulation with an exclusive delivery system for the treatment of dry lip conditions. PuraCap Pharmaceutical is the maker of EpiCeram® Controlled Release Skin Barrier Emulsion, a leading prescription product indicated […]
PuraCap Pharmaceutical Seeks Damages From InvaGen for Contract Violation
NEW YORK, Oct. 23, 2015 /PRNewswire/ — PuraCap Pharmaceutical, LLC announced that it has instituted a civil lawsuit against InvaGen Pharmaceuticals, Inc. and Exelan Pharmaceuticals, Inc. (collectively, "InvaGen") in the United States District Court for the Southern District of New York, at Civil No. 15-cv-8222. In its Complaint, PuraCap Pharmaceutical alleges that InvaGen breached certain obligations […]
PuraCap(TM) Pharmaceutical Introduces Unique EpiCeram(R) 225g Airless Pump
EpiCeram(R) Controlled Release Skin Barrier Emulsion now offers dosing flexibility with 2 sizes SOUTH PLAINFIELD, N.J., July 9, 2014 /PRNewswire/ — PuraCap(TM) Pharmaceutical today announced the newest addition to the EpiCeram(R) product line, the EpiCeram(R) 225g Airless Pump. The unique airless pump gives patients more EpiCeram(R) to treat any size area of atopic dermatitis. The special […]
PuraCap Pharmaceutical Announces Site Visit by US Ambassador to China
Max Baucus, US Ambassador to China visits Wuhan Softgel Capsule Manufacturing Plant in Wuhan China SOUTH PLAINFIELD, N.J., May 19, 2014 /PRNewswire/ — PuraCap Pharmaceutical today announced the visit of Max Baucus, US Ambassador to China, to the PuraCap Softgel Capsule Manufacturing Plant in Wuhan, China on May 14, 2014. Ambassador Baucus had the opportunity […]
EpiCeram® Skin Barrier Treatment Administered to Babies at High Risk for Eczema SOUTH PLAINFIELD, N.J., Feb. 27, 2014 /PRNewswire/ — PuraCap™ Pharmaceutical today announced its supportive participation in the "Prevention of Eczema by a Barrier Equilibrium Strategy" Trial conducted under the sponsorship of the Murdoch Children's Research Institute and in collaboration with the University of […]
PuraCap’s Team EpiCeram® Joins Walk to Cure Eczema
SOUTH PLAINFIELD, N.J., May 22, 2013 /PRNewswire/ — Team EpiCeram is proud to announce its support of the National Eczema Association's "Itching for a Cure" walk in New Jersey on June 8, 2013. Working together with the National Eczema Association, Team EpiCeram hopes to build awareness of eczema and help raise funds for a cure. More […]
